Novel Therapeutics for HR+/HER2- Metastatic Breast Cancer

Download this slideset to explore future directions in the treatment of HR+/HER2- metastatic breast cancer, including a review of novel agents in the setting of resistance to standard-of-care therapies.
Joyce O'Shaughnessy, MD
Program Director
Format: Microsoft PowerPoint (.ppt)
File Size: 2.49 MB
Released: December 11, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
Immunomedics, Inc.
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

From Clinical Care Options (CCO), on-demand Webcast with Lee Schwartzberg, MD, FACP, and Ruth O’Regan, MD, on optimal treatment of breast cancer brain metastases

Ruth O'Regan, MD Lee Schwartzberg, MD, FACP Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) Released: January 22, 2021 Expired: January 21, 2022

Expert video from live CCO Webinar on using immune checkpoint inhibitors and antibody–drug conjugates for early-stage through metastatic TNBC

Heather McArthur, MD, MPH
Program Director
Kevin Kalinsky, MD, MS Rita Nanda, MD
Physicians: maximum of 1.25 AMA PRA Category 1 Credits ABIM MOC: maximum of 1.25 Medical Knowledge MOC point(s) Released: January 22, 2021 Expired: January 21, 2022

Commentary by Dr. Kevin Kalinsky: Sequencing checkpoint inhibitors and sacituzumab govitecan in advanced TNBC with vs without BRCA mutation, from CCO

Kevin Kalinsky, MD, MS Released: December 23, 2020

Downloadable slideset with key data from the 2020 SABCS Virtual Symposium from Clinical Care Options (CCO)

Sara Hurvitz, MD, FACP Joyce O'Shaughnessy, MD Released: December 18, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue